

PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION

## Finance Executive David Belitz Joins Solas BioVentures

*As a partner, David Belitz brings extensive leadership experience and financial expertise from the investment service industry.*

**Chattanooga, Tennessee (August 29, 2022)** - Solas BioVentures is excited to welcome a new partner, David Belitz, to its Chattanooga headquarters. With 25 years of executive experience in the financial services industry, David will lead Solas's financial due diligence team to review new investments and continually monitor and review the existing portfolio.

In addition to bringing to Solas extensive financial leadership experience, David has an outstanding record in building and managing high-performance teams in the financial service industry. Currently, he serves as the CEO of The Lupton Company, where he joined as controller in 1997. Since 2009, David has served as a founding general partner of the Chattanooga Renaissance Funds (I and II), a series of angel funds investing in seed and early-stage businesses. He also serves on the investment committee of the Benwood Foundation and the endowment committee of the University of Chattanooga Foundation.



*Solas BioVentures  
Partner, David Belitz*

Mr. Belitz holds a BS degree in Business Administration and a Master of Accountancy degree from the University of Tennessee at Knoxville. His Master of Business Administration (MBA) degree is from the University of Tennessee in Chattanooga.

“David leading the financial review and monitoring of potential and current portfolio companies is invaluable for supporting our continued growth,” said Dr. David Adair, Co-Founder and Managing General Partner of Solas BioVentures. “His decades of experience and reputation for exemplary fiscal oversight will help ensure we’re doing everything we can to support our portfolio companies wisely while maximizing returns. He is a welcomed partner in our quest for seismic contributions to patients and their families.”

### About Solas BioVentures

Solas BioVentures is a venture capital firm that invests exclusively in the life science industry, focusing on early and development stage Biotech and MedTech companies advancing impactful, disruptive technologies. Headquartered in Chattanooga, Tennessee, its coverage is global. For more information, visit [solasbio.com](https://solasbio.com).